Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Canadian Natural Resources Ltd. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Canadian Natural Resources Ltd. trades at $42.24 (market cap $84.83B). The key difference: Canadian Natural Resources Ltd. is far larger — about 18.9× ACADIA Pharmaceuticals Inc.'s market cap, and Canadian Natural Resources Ltd. pays a 4.32% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CNQ | |
|---|---|---|
Market Cap | $4.49B | $84.83B |
Sector | Health | Energy |
52-Week High | $28.06 | $50.55 |
52-Week Low | $20.06 | $29.31 |
Enterprise Value | $3.69B | $96.06B |
Dividend Yield | — | 4.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Canadian Natural Resources (CNQ) trades at $40.69, up 2.65% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows attractive valuation metrics with P/E of 11.8 and robust profitability including 24.5% net margin. Technical indicators signal bearish sentiment despite recent price strength, while analyst consensus remains overwhelmingly positive with 75% buy ratings. Recent dividend declarations and strong cash flow generation support shareholder returns.
CNQ presents a compelling value opportunity with solid fundamentals and positive earnings surprises, though technical weakness and oil price volatility pose near-term risks. The company's strong balance sheet and consistent dividend payments provide downside protection, while operational efficiency and production growth drive long-term potential. Investors should weigh valuation appeal against energy sector cyclicality and technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
